Inovio's Voceryq Receives Accelerated FDA Approval as First US DNA Medicine

The U.S. FDA has granted accelerated approval to Inovio Pharmaceuticals' Voceryq (INO-3107), making it the first FDA-approved DNA medicine in the United States. This approval is for reducing the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP), based on a 27% clean-response rate observed in a 26-patient study. This milestone could pave the way for future DNA-based therapies.